4
Changes in Ownership
NEKTAR THERAPEUTICS Filed Acc 0001209191-22-046489
Chief R&D Officer sold 10,560 shares at $4.76 ($50,266)
- Chief R&D Officer acquired 135,000 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Zalevsky Jonathan Chief R&D Officer | 2022-08-15 | Grant or award | +135,000 | 411,399 | D | ||
| Zalevsky Jonathan Chief R&D Officer | 2022-08-16 | Sale | −10,560 | $4.76 | $50,266 | 400,839 | D |
| Derivatives | |||||||
| Zalevsky Jonathan Chief R&D Officer | 2022-08-15 | Grant or award · Common Stock | +270,000 | 270,000 | D | ||
| Open-market sales · 10,560 sh · avg $4.76 · $50,266 | |||||||
Loading xslF345X03/doc4.xml…